ATLANTA, April 20, 2012 /PRNewswire/ –Data examining the effect of Neupro (rotigotine transdermal system) in both Parkinson’s disease and Restless Legs Syndrome (RLS) will be presented at the 64th American Academy of Neurology (AAN) Annual Meeting in New Orleans, LA, between April 21-28, 2012. Key data presentations will focus on post hoc analyses of pivotal and other studies of rotigotine transdermal system and are designed to investigate the impact of rotigotine transdermal system on the core symptoms of RLS and on the motor and underlying symptoms of Parkinson’s disease such as depression, anxiety, anehdonia, fatigue and pain.

“These resultsaddto thebody of clinical evidencesupporting rotigotine transdermal system. The dataunderscore UCB’s continuing commitment to discovering and developing therapies that address unmet medical needs for potentially debilitating central nervous system disorders,” said Dr. James Zackheim, PhD, Senior Medical Director, Central Nervous System Business Unit, UCB, Inc.

Earlier this month, the U.S. Food and Drug Administration (FDA) approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and as a treatment for moderate-to-severe primary RLS. Neupro was previously approved by the FDA for the signs and symptoms of early stage idiopathic PD. The FDA has also approved UCB’s new formulation of Neupro.

Following is a guide to UCB-supported research featuring rotigotine transdermal system being presented during the AAN Annual Meeting. For more information please contact Andrea Levin at 404.483.7329 or Andrea.Levin@ucb.com.

Parkinson’s disease abstracts

1. [P.06.088] Abstract Title: Rotigotine Transdermal System Improves Neuropsychiatric Features (Apathy, Anhedonia, Anxiety, and Depression) and Fatigue in Patients With Parkinson’s Disease: A Post-hoc Analysis of Five Double-blind Placebo-controlled Studies Date/Time: Thursday, April 26, 20127:30 am 12:00 pm Session Info:Session P06: Assessment and Treatment of Parkinson’s Disease

2. [P.06.085] Abstract Title: Rotigotine Transdermal System Improves Pain in Patients With Parkinson’s Disease: A Post-hoc Analysis of Patients Reporting Pain in the RECOVER StudyDate/Time: Thursday, April 26, 20127:30 am 12:00 pm Session Info:Session P06: Assessment and Treatment of Parkinson’s Disease

3. Abstract Title: An International Study to Investigate Rotigotine Dose Response (2-8 mg/24 h) on ‘Off’ Time in Patients With Advanced Stage Parkinson’s Disease Date/Time: Wednesday, April 25, 2012 5:45 pm 7:00 pm

RLS abstracts

4. [P04.032] Abstract Title: Effects of 24-h Transdermal Delivery of Rotigotine on the Core Symptoms and Symptom Impact of Restless Legs Syndrome/Willis-Ekbom Disease: A Post-hoc Analysis of IRLS Single Item Data from a 6-month Placebo-controlled European StudyDate/Time:Wednesday, April 25, 20127:30 am 12:00 pm Session Info:Session P04: Movement Disorders: Restless Legs Syndrome, and Tardive Dyskinesia

Continue reading here:
New Neupro® Data in Parkinson's Disease and Restless Legs Syndrome to be Presented at the 64th American Academy of …

Source:
http://www.longevitymedicine.tv/feed/